Furthermore, nivolumab plus ipilimumab was shown to be superior to dabrafenib plus trametinib as first-line therapy in patients with BRAF V600E/K-mutant metastatic melanoma,11,12 suggesting that combination immunotherapy may be a preferred option whenever feasible. Here, BRAF is linked to metastatic melanoma.